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A RELIABLE screening test for malignant disease has long been sought but of
the many tests devised, using a wide variety of techniques, none is sufficiently
reliable for routine use.
In attempts to produce such a screening test the trypsin inhibitor activity
of serum has often been used and many methods have been introduced to measure
this inhibitor activity (Peacock and Sherry, 1952; Homer, Katchman and Zipf,
1963). Most of the methods have used one or other of a variety of substrates
which have been capable of hydrolysis by a wide range of proteolytic enzymes
rather than by trypsin specifically.
Nardi (1958) described a technique for the estimation of serum trypsin using
the substrate benzoyl-l-arginine amide hydrochloride (BAA). His findings
could not be confirmed (Kemp, 1959, unpublished; Babson, Williams and
Phillips, 1962) but in the course of the work a method of estimating the trypsin
inhibitor activity of serum has been devised using BAA as a substrate. Although
at first it was thought that BAA was specifically hydrolysed by trypsin, Nardi
(1959, personal communication) later recognised that it may also be hydrolysed
by the plant enzyme papain and by plasmin (fibrinolysin), the effect of the latter
in his determination being considered negligible. Plasmin may be produced
by the trypsin activation of plasminogen and the specificity of any test for serum
trypsin or serum trypsin inhibitor activity using BAA may therefore be reduced.
The evidence concerning activation of plasminogen by trypsin is conflicting but
if trypsin is present in excess any plasmin formed is rapidly destroyed (Astrup,
1956).
It seems unlikely therefore that plasmin plays a significant role in the present
method which, with its more specific substrate, has been used to re-evaluate
serum trypsin inhibitor activity as a screening test for the detection of malignant
disease.
MATERIALS
Reagents
(1) Trypsin solution.-Crystallised salt free trypsin (Armour Pharmaceutical
Company Ltd.) is stored in a dessicator at -20° C. 8 mg. of this trypsin (2500
units/mg.) are dissolved in 10 ml. N/1IO HCI and immediately returned to -20° C.
in 1 ml. quantities. Any unused reagent is discarded after 10 days.
(2) Phosphate buffer M/15. pH 7-8.-Solution A. 0X908 g. of potassium
dihydrogen orthophosphate (KH2PO4) is dissolved in distilled water and made
up to 100 ml.
Solution B. 11-876 g. of disodium hydrogen orthophosphate dihydrateSERUM TRYPSIN INHIBITOR ACTIVITY
(Na2HPO4 . 2H20) are dissolved in distilled water and made up to 1 litre. Add
85 ml. of solution A to 915 ml. of solution B.
(3) Buffered substrate.-An 0 05 M solution of benzoyl-l-arginine amide hydro-
chloride monohydrate (BAA) (Mann Research Laboratories, Inc., New York
6, N.Y.) is prepared by dissolving 50 mg. of the pure substance in 3-0 ml. of
the phosphate buffer. This solution is stored at -20° C. and is stable for a
minimum period of 3 months.
(4) 10 per cent sodium tungstate.
(5) 2/3 N sulphuric acid.
(6) Tungstic acid solution.-To 2*5 ml. of (4) add 3 0 ml. of (5) immediately
before use.
(7) Gum ghatti solution.-1 g. ofpowdered gum ghatti is suspended in a muslin
bag in 1 litre of distilled water for 24 hours. The bag is then removed, 10 ml.
of chloroform are added and well shaken.
(8) Nessler's reagent (B.D.H.).
Sera
Serum was obtained, as far as possible without selection, from hospital in-
patients and from out-patients attending this laboratory. The staffof the labora-
tory and other apparently healthy persons form the group of normal controls.
5 ml. of blood was taken in a clean, dry syringe, transferred to a test tube and
allowed to clot. Serum was separated within 3 hours of collection and stored at
4C. overnight, a 1 in 8 dilution in distilled water being made immediately before
use.
METHOD
0 05 ml. of the buffered substrate is added to each of four chemically clean
test tubes. Trypsin solution (0.05 ml.) is added to the standard, test and control
tubes, 0*05 ml. serum (1: 8 dilution) to the test tube, and 0 05 ml. distilled water
to the standard and blank tubes.
After shaking, thetubes are incubated for 60 minutes at 370 C. in a water bath.
Diluted serum (0.05 ml.) and trypsin solution (0.05 ml.) are then added to the
control and blank tubes respectively and 0 55 ml. tungstic acid solution to each
tube. All tubes are shaken, allowed to stand for 15 minutes and centrifuged.
To 0*5 ml. of each supernatant 2-5 ml. of gum ghatti solution are added.
After mixing the tubes are left until any slight turbidity disappears and 0.5 ml.
Nessler's reagent is then added and the tubes again mixed.
The final mixture is read in a spectrophotometer at 440 m/t, the blank being
used to zero.
Calculation:
T O x 40X 005 X = mg. trypsin inhibited by 1 0 ml. serum.
i.e.
C x 64 = mg. trypsin inhibited by 1 0 ml. serum.
RESULTS
Serum trypsin inhibitor activity (STIA) has been estimated in 1043 individuals
and the clinical conditions and numbers of persons as well as the values for the
mean, standard deviation and range are detailed in Table I.
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TABLE I.-Details of Number of Cases, Range of Values, Mean and
Standard Deviationfor Each Condition
Condition
Normal
Pregnancy-normal.
Pregnancy-complicated .
Gynaecological
Inflammation-acute
Inflammation-chronic
Asthma and chronic bronchitis
Nephritis chronic .
Sarcoidosis
Tuberculosis
Arthritis
Miscellaneous
Peptic ulcer
Diabetes mellitus
Gastro-intestinal haemorrhage
Haematuria
Renal calculus
Cerebral thrombosis .
Addison's disease
Paget's disease of bone
Cerebral arteriosclerosis
Anaemia (various)
Jaundice (various)
Rheumatic heart disease (chronic)
" Dyspepsia" .
Myxoedema
Thyrotoxicosis
Hypertension (essential)
Myocardial infarction
Myocardial ischaemia
Prostatic hypertrophy
Tumours-benign
Carcinoma-colon
Carcinoma-prostate
Carcinoma-stomach
Carcinoma-lung
Carcinoma bladder
Carcinoma-breast
Carcinoma-ovary
Carcinoma-cervix
Carcinoma-miscellaneous
Carcinoma-primary unknown
Leukaemia and myelomatosis
Sarcoma and reticulosis
Cerebral tumour
Post-operative and trauma
Number
of cases Range Mean S.D.
64 . 0-2-1-0 0-49 . 0-18
17 . 1-1-2-5 . 1-54 . 0-37
16 . 1-1-3-2 . 2-12 . 0-53
12 . 0-4-11 . 0-77 . 0-26
79 . 0-3-6-0 . 2-32 . 1-13
17 . 0-3-2-7 . 0-98 . 0-65
28 . 0-2-3-0 . 1-06 . 0-66
10 0-6-1-3 . 0-94 0-79
5 0-4-1-4 . 0-86 0-46
11 . 0-3-1-5 . 0-92 . 0-51
47 0-2-2-9 . 0-99 . 0-59
92 . 0-2-3-4 . 1-13 . 0-68
21 . 0-2-2-1 . 1-12 0-52
19 0-2-2-4 . 1-02 0-66
26 . 0-4-3-5 . 1-37 0-84
3 . 1-5-2-1 . 1-78 0-25
10 . 0-4-2-8 . 1-28 . 0-70
7 0-4-2-5 . 1-20 . 0-88
3 . 0-4-1-2 . 0-83 . 0-40
6 . 03-4-7 1-35 . 1-71
10 . 0-3-2-2 . 0-92 0-54
11 . 0-3-2-5 . 1-05 0-77
21 . 0-5-2-2 . 1-20 0-40
9 0-6-2-2 . 1-42 . 0-51
34 . 02-1-9 0-84 0-45
21 0-2-1-6 . 0-71 0-40
10 . 0-5-2-0 . 1-00 . 0-41
75 . 0-2-2-5 0-87 . 0-48
56 . 1-0-5-6 . 3-22 . 1-30
33 . 0-3-2-9 . 1-40 . 0-65
37 . 0-2-5-6 . 1-28 1-04
14 0-4-1-8 . 0-98 0-49
32 0-5-5-5 . 2-69 1-45
18 . 0-8-5-5 . 3-37 1-48
14 . 0-7-5-8 . 2-36 1-76
15 . 0-3-5-8 2-81 1-62
10 0-65-1 . 2-09 1-27
10 . 0-6-2-4 . 1-25 0-63
6 0-9-5-0 . 3-11 1-53
14 . 0-5-5-5 . 2-1 1-61
26 0-5-9 . 2-24 . 1-59
7 . 07-5-9 . 2-96 . 1-77
7 0-3-2-5 1-65 . 0-94
5 . 1-1-3-0 . 2-0 . 1-17
3 . 0-8-2-1 1-27 . 0-75
52 0-9-5-8 . 2-72 . 1-28
The cases have also been divided into three main groups, normal, malignant
and miscellaneous non-malignant conditions, and the distribution of values in
each of these three groups is shown in Fig. 1. The narrow range of the "normal"
group contrasts sharply with the wide distribution of values in the other two
groups.
In previous work of this nature (Cliffton, 1950) it was noted that certain
conditions, particularly pregnancy, acute inflammation and post-operative states,
are frequently associated with a high STIA: this was confirmed in the present
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series and a high STIA was also noted in many cases of myocardial infarction
(Table I). The distribution of the values for these four conditions are separately
shown in Fig. 2.
The cases in these four conditions have been removed from the miscellaneous
non-malignant group and the distribution of values of the remaining cases is
shown in Fig. 3.
NORMAL
10 Number 64
Mean 0 49
S.D. 0-18
u
O_ MALIGNANT NEOPLASMS
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$! Mean 2-44
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S.D. 1-07
0 d_ l l l
10 2-0 3-0 4.0 5.0 6.0
mg. TRYPSIN INHIBITED BY 1-0 ml. SERUM
FIG. 1.-Distribution ofvalues for normal individuals and for hospital patients with and without
malignant disease.
Calculation of normal and abnormal ranges
A normal range of values has been calculated using the results in the group
of normal persons only by assuming that the mean + 3 S.D. will include the
highest value. Mean (0.49) + 3 S.D. (0.54) = 1-03.
An intermediate- range was calculated for the group of miscellaneous non-
malignant hospital cases, excluding those conditions known to have a high STIA
(pregnancy, acute inflammation, post-operative states, myocardial infarction)
(Fig. 3). The upper limit of this range was taken as the mean + 2 S.D. (2. 33)394 J. H. KEMP AND J. M. JOHNSTONE
PREGNANCY
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S.D. 0-52
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U ~~~~~~~~~~~~~~~~~~ S.D. 1-13
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FiG. 2.-Distribution ofvalues for pregnancy, acute inflammation, post-operative and traumatic,
and myocardial infarction groups.
thus allowing for a theoretical 5 per cent of false positive (abnormal) results%
generally accepted in assessing tests of this nature.
Values of 2 -4 and above were considered abnormal.
DISCUSSION
In assessing the merit of any screening test for the detection of malignant-
disease it has been stated that the test should give a positive (abnormal) result
in at least 90 per cent of cases of malignancy and give not more than 5 per cent
of " false " positive results (Dunn and Greenhouse, 1950) and the figures in this.
series have therefore been calculated as percentages (Table II).SERUM TRYPSIN INHIBITOR ACTIVITY
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',
X1 Number 592
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FIG. 3.-Distribution of values for the miscellaneous non-malignant hospital group excluding
the four groups in Fig. 2.
TABLE II.-Percentages of Cases with a Normal, Intermediate or
Abnormal STIA Value in the Main Groups
Serum trypsin inhibitor activity
Numnber A I
Condition of cases 0-1 0 1-1-2-3 2 -4 and above
Normal . . . . 64 . 64 (100%)
Malignant disease . . . . 167 . 37 (22.2%) 55 (33%) 75 (44.8%)
Miscellaneous non-malignant conditions 812 360 (44.3%) 320 (39-4%) 132 (16-3%)
Miscellaneous non-malignant conditions (ex- 592 . 346 (58-5%) 220 (37.2%) 26 (4-3%)
cluding pregnancy, acute inflammation,
post-operative states and myocardial in-
farction)
On the basis ofthe above requirements this test fails as a satisfactory screening
test for malignant disease as the STIA was not regularly raised in malignant
disease. In fact the STIA value was 2-4 or above in only 45 per cent of the
cases of malignant disease.
This lack of specificity does not mean, however, that the test is without a
certain limited value. In " normal " individuals the values are low and no false
positive result has been found. Further, in the miscellaneous non-malignant
group of hospital cases, provided that certain relatively readily recognised con-
ditions (pregnancy, acute inflammation, post-operative states and myocardial
infarction) are excluded, the false positive results are less than 5 per cent.
A normal value does not exclude the presence of malignant disease. Con-
versely, however, a consistently abnormal STIA merits detailed investigation
and is usually indicative of some form of disease.
SUMMARY
Serum trypsin inhibitor activity has been estimated in 1043 individuals by a
method using benzoyl-l-arginine amide hydrochloride (BAA) which is a more
specific substrate for tryptic hydrolysis than those previously used for this
purpose. The method is unsatisfactory as a general screening test for malignant
disease but a high value, in the absence of certain conditions (acute inflammation,
post-operative states, myocardial infarction and pregnancy), indicates the need
for further investigation of the patient.
A grant from the Sheffield Regional Hospital Board in support of this work
is gratefully acknowledged.
395396 J. H. KEMP AND J. M. JOHNSTONE
REFERENCES
ASTRUP, T.-(1956) Blood, 11, 781.
BABSON, A. L., WILLIAMS, P. A. R. AND PHILLIPS, G. E.-(1962) Clin. Chem., 8, 62.
CLIFFTON, E. E.-(1950) J. nat. Cancer Inst., 11, 33.
DUNN, J. E. AND GREENHOUSE, S. W. (1950) Federal Security Agency, Public Health
Service, Publication 9, cited by Peacock, A. C. and Sherry, J. J. (1952).
HOMER, G. M., KATCHMAN, B. J. AND ZIPF, R. E.-(1963) Clin. Chem., 9, 428.
NARDI, G. L.-(1958) J. Lab. clin. Med., 52, 66.
PEACOCK, A. C. AND SHERRY, J. J.-(1952) J. nat. Cancer Inst., 12, 861.